Figure 1.

CYD0618 exhibits a potent inhibitory activity in human ovarian cancer cells. A, chemical structure of CYD0618. B, human ovarian cancer cells (5000 cells/well) were treated with the indicated concentrations of CYD0618 for 72 h. The cell growth was then assessed using SRB staining, and IC₅₀ values were calculated. C, ovarian cancer cells were treated with CYD0618 (0.3 and 1 μm) for 24 h. Cells were then washed, allowed to form colonies for additional 12 days, stained with crystal violet, and then counted. D, CYD0618 alters the cell cycle distributions of ovarian cancer cells. Representative cell-cycle analysis is shown for A2780 and OVAR8 cells treated with DMSO or CYD0618 as indicated for 24 h using flow cytometry. E, cells were treated with CYD0618 for 24 h and then subjected to apoptosis analysis using annexin V/PI staining by flow cytometry. F, CYD0618 induces PARP cleavage in ovarian cancer cells. Whole-cell lysates from vehicle- or CYD0618-treated cells were analyzed by Western blotting using the indicated antibodies. G, wound-healing assay was performed for evaluating the anti-metastatic effect of CYD0618. Confluent monolayers of A2780 and SKOV3 cells were scarred, and the repair was monitored microscopically after 24 h of treatment CYD0618. Data are expressed as mean ± S.D., n = 3. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 versus vehicle control.